BACKGROUND: Diamond Blackfan anemia (DBA) is a genetically and clinically heterogeneous ribosomopathy and inherited bone marrow failure syndrome characterized by anemia, reticulocytopenia, and decreased erythroid precursors in the bone marrow with an increased risk of malignancy and, in approximately 50%, physical abnormalities. METHODS: We retrospectively analyzed clinical data from 77 patients with DBA born in the Russian Federation from 1993 to 2014. In 74 families there was one clinically affected individual; in only three instances a multiplex family was identified. Genomic DNA from 57 DBA patients and their first-degree relatives was sequenced for mutations in RPS19, RPS10, RPS24, RPS26, RPS7, RPS17, RPL5, RPL11, RPL35a, and GATA1. RESULTS: Severe anemia presented before 8 months of age in all 77 patients; before 2 months in 61 (78.2%); before 4 months in 71 (92.2%). Corticosteroid therapy was initiated after 1 year of age in the majority of patients. Most responded initially to steroids, while 5 responses were transient. Mutations in RP genes were detected in 35 of 57 patients studied: 15 in RPS19, 6 in RPL5, 3 in RPS7, 3 each in RPS10, RPS26, and RPL11 and 1 each in RPS24 and RPL35a; 24 of these mutations have not been previously reported. One patient had a balanced chromosomal translocation involving RPS19. No mutations in GATA1 were found. CONCLUSION: In our cohort from an ethnically diverse population the distribution of mutations among RP genes was approximately the same as was reported by others, although within genotypes most of the mutations had not been previously reported.
BACKGROUND: Diamond Blackfan anemia (DBA) is a genetically and clinically heterogeneous ribosomopathy and inherited bone marrow failure syndrome characterized by anemia, reticulocytopenia, and decreased erythroid precursors in the bone marrow with an increased risk of malignancy and, in approximately 50%, physical abnormalities. METHODS: We retrospectively analyzed clinical data from 77 patients with DBA born in the Russian Federation from 1993 to 2014. In 74 families there was one clinically affected individual; in only three instances a multiplex family was identified. Genomic DNA from 57 DBA patients and their first-degree relatives was sequenced for mutations in RPS19, RPS10, RPS24, RPS26, RPS7, RPS17, RPL5, RPL11, RPL35a, and GATA1. RESULTS: Severe anemia presented before 8 months of age in all 77 patients; before 2 months in 61 (78.2%); before 4 months in 71 (92.2%). Corticosteroid therapy was initiated after 1 year of age in the majority of patients. Most responded initially to steroids, while 5 responses were transient. Mutations in RP genes were detected in 35 of 57 patients studied: 15 in RPS19, 6 in RPL5, 3 in RPS7, 3 each in RPS10, RPS26, and RPL11 and 1 each in RPS24 and RPL35a; 24 of these mutations have not been previously reported. One patient had a balanced chromosomal translocation involving RPS19. No mutations in GATA1 were found. CONCLUSION: In our cohort from an ethnically diverse population the distribution of mutations among RP genes was approximately the same as was reported by others, although within genotypes most of the mutations had not been previously reported.
Authors: T N Willig; C M Niemeyer; T Leblanc; C Tiemann; A Robert; J Budde; A Lambiliotte; E Kohne; G Souillet; S Eber; J L Stephan; R Girot; P Bordigoni; G Cornu; S Blanche; J M Guillard; N Mohandas; G Tchernia Journal: Pediatr Res Date: 1999-11 Impact factor: 3.756
Authors: Vijay G Sankaran; Roxanne Ghazvinian; Ron Do; Prathapan Thiru; Jo-Anne Vergilio; Alan H Beggs; Colin A Sieff; Stuart H Orkin; David G Nathan; Eric S Lander; Hanna T Gazda Journal: J Clin Invest Date: 2012-06-18 Impact factor: 14.808
Authors: T N Willig; N Draptchinskaia; I Dianzani; S Ball; C Niemeyer; U Ramenghi; K Orfali; P Gustavsson; E Garelli; A Brusco; C Tiemann; J L Pérignon; C Bouchier; L Cicchiello; N Dahl; N Mohandas; G Tchernia Journal: Blood Date: 1999-12-15 Impact factor: 22.113
Authors: Jason E Farrar; Paola Quarello; Ross Fisher; Kelly A O'Brien; Anna Aspesi; Sara Parrella; Adrianna L Henson; Nancy E Seidel; Eva Atsidaftos; Supraja Prakash; Shahla Bari; Emanuela Garelli; Robert J Arceci; Irma Dianzani; Ugo Ramenghi; Adrianna Vlachos; Jeffrey M Lipton; David M Bodine; Steven R Ellis Journal: Am J Hematol Date: 2014-08-04 Impact factor: 10.047
Authors: Lisa Mirabello; Elizabeth R Macari; Lea Jessop; Steven R Ellis; Timothy Myers; Neelam Giri; Alison M Taylor; Katherine E McGrath; Jessica M Humphries; Bari J Ballew; Meredith Yeager; Joseph F Boland; Ji He; Belynda D Hicks; Laurie Burdett; Blanche P Alter; Leonard Zon; Sharon A Savage Journal: Blood Date: 2014-05-14 Impact factor: 25.476
Authors: Disha-Gajanan Hiregange; Andre Rivalta; Ada Yonath; Ella Zimmerman; Anat Bashan; Hagith Yonath Journal: FEBS Open Bio Date: 2022-06-06 Impact factor: 2.792
Authors: Anna Aspesi; Marta Betti; Marika Sculco; Chiara Actis; Cristina Olgasi; Marcin W Wlodarski; Adrianna Vlachos; Jeffrey M Lipton; Ugo Ramenghi; Claudio Santoro; Antonia Follenzi; Steven R Ellis; Irma Dianzani Journal: Hum Mutat Date: 2018-05-28 Impact factor: 4.878
Authors: Matthew D Gianferante; Marcin W Wlodarski; Evangelia Atsidaftos; Lydie Da Costa; Polyxeni Delaporta; Jason E Farrar; Frederick D Goldman; Maryam Hussain; Antonis Kattamis; Thierry Leblanc; Jeffrey M Lipton; Charlotte M Niemeyer; Dagmar Pospisilova; Paola Quarello; Ugo Ramenghi; Vijay G Sankaran; Adrianna Vlachos; Jana Volejnikova; Blanche P Alter; Sharon A Savage; Neelam Giri Journal: Haematologica Date: 2021-05-01 Impact factor: 9.941
Authors: Aleksey S Tsukanov; Dmitriy Y Pikunov; Vitaly P Shubin; Aleksey A Barinov; Vladimir N Kashnikov; Yuri A Shelygin; Andrey D Kaprin; Elena V Filonenko; Dmitriy V Sidorov; Aleksey A Maschan; Galina A Novichkova; Liudmila A Yasko; Elena V Raykina; Aleksandr G Rumyantsev Journal: Front Oncol Date: 2021-04-16 Impact factor: 6.244